Intracavernous prostaglandin E1 in erectile dysfunction

The Clinical Investigator

Volumn 72, Issue 2, 1994, Pages 139-149

  Linet, O I ^a   Neff, L L ^a  

^a PFIZER INC   (United States)

Author keywords

Diagnosis; Erectile dysfunction; Intracavernous injection; Prostaglandin E1; Selfinjection treatment; Side effects

Indexed keywords

PLACEBO; PROSTAGLANDIN E1; PROSTAVASIN; XENON 133; DIAGNOSTIC AGENT;

ADULT; FIBROSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PENIS ERECTION; REVIEW; DRUG EFFECT; DRUG SELF ADMINISTRATION; IMPOTENCE; INJECTION; METABOLISM; PENIS;

ALPROSTADIL; HUMAN; IMPOTENCE; INJECTIONS; MALE; PENILE ERECTION; PENIS; SELF ADMINISTRATION;

EID: 0028182755     PISSN: 09410198     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/BF00184593     Document Type: Article

References (117)

1. Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates
2. Why intracavernous PGE1 for diagnosis and treatment of impotence?
3. Treatment of erectile impotence in renal transplant patients with intracavernosal vasoactive drugs
4. Intracavernous drug infusion: considerations on studies performed in the past decade and new findings involving PGE1
5. Self-administration in the pharmacological treatment of impotence
6. An improved vasoactive drug combination for a pharmacological erection program
7. Prostaglandin E1 in the therapy of erectile deficiency
8. New perspectives in the treatment of post-traumatic, neurologic erectile failure
9. Intracavernous injections of prostaglandin E, in the treatment of erectile dysfunctions
10. The prostaglandins: a family of biologically active lipids
11. Penile angiography: the last angiographic frontier
12. Changes in penile hemodynamics after intracavernous injection of prostaglandin E1 and prostaglandin I2 in pigtail monkeys
13. Therapeutic results with PGE1 in the treatment of erectile dysfunction
14. Intracavernosal vasoactive agents, comparison of diabetic and non-diabetic impotent men
15. Diagnostic value of intracavernous injection of 20 mg prostaglandin E1 in erectile dysfunction
16. Non invasive detection of venogenic impotence: real-time US evaluation of periprostatic (Santorini's) venous plexus after (PGE1) induced erection
17. Comparison of effects following intracorporeal injection of papaverine and prostaglandin El
18. Prostaglandin E1 versus papaverine for diagnosis of erectile dysfunction
19. Evaluation of the efficacy of a prostaglandin E1 solution in the diagnosis of impotence
20. Effects of prostaglandins E-1, E-2, F-1a and F-2a on human sperm motility
21. Intracavernosal injection therapy for impotence due to spinal cord injury
22. Prostaglandin E1 therapy for impotence, comparison with papaverine
23. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury
24. Intracavernous injection of prostaglandin El in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone
25. Pharmacological erection program using prostaglandin El
26. Quantitative measurement of prostaglandins and thromboxanes: general considerations
27. Measurement of prostaglandins, thromboxanes, prostacyclin and their metabolites by gas liquid chromatography-mass spectrometry
28. Fate of prostaglandins E1 and A1 in the human pulmonary circulation
29. The hemodynamic effect of intracavernous injection of prostaglandin E1 compared with papaverine-regitine; a Doppler analysis
30. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery
31. The prostaglandins. Biochemical, physiologic and clinical considerations
32. Prostaglandins
33. Comparison of penile vascular effect induced by intracavernous injection of papaverine and prostaglandin E1
34. Impotence evaluated by the use of prostaglandin E1
35. Dynamic penile washout test. Xe-133 washout study after prostaglandin El intracavernous injection
36. Histopathological change of corpora cavernosa after long-term intracavernous injection
37. Therapeutic intracavernous injection of a vasoactive drug for mild arterial impotence
38. Duplex echo-Doppler and intracavernous injection of prostaglandin El in the diagnosis of impotence
39. Intracavernous injection of prostaglandin E1: the diagnosis of venogenic impotence
40. Intracavernous injection of prostaglandin E1: the application to cavernosography and penile blood flow measurement for the diagnosis of venogenic impotence
41. Studies on male sexual impotence report 18: therapeutic trial with prostaglandin E1 for organic impotence
42. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence
43. Pharmacotherapy of erectile dysfunction: a review
44. Double-blind, crossover study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence
45. Contraction and relaxation of the retractor penis muscle and the penile artery of the bull. A study of effects of drugs and transmural nerve stimulation on isolated smooth muscle strips
46. Comparative study of some isolated mammalian smooth muscle effectors of penile erection
47. Color-coded duplex sonography in impotence: significance of different flow parameters in patients and controls
48. Impotence
49. Intracavernous injection of prostaglandin E1 as a diagnostic test in erectile dysfunction
50. Therapeutic pharmacologic erections
51. Prostaglandin El versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison
52. Comparison of the effects of papaverine versus prostaglandin El on penile blood flow by color duplex sonography
53. Treatment of impotence: comparison between the efficacy and safety of intracavernous injection of papaverine plus phentolamine (regitine) and prostaglandin E1
54. Comparative value of prostaglandin El and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients
55. Prostaglandin-E1 oneway syringes for routine diagnostic of erectile dysfunction
56. Preliminary experience with prostaglandin E1 and PGE1 ready-to-use injections
57. The use of prostaglandines for diagnosis and treatment of erectile impotence
58. Penile pharmacological duplex ultrasonography: a dose-effect study comparing papaverine, papaverine/phentolamine and prostaglandin E1
59. A study on impotence: treatment of impotence with prostaglandin E1
60. Penile xenon (Xe-133) washout: a rapid method of screening for vasculogenic impotence
61. Intracavernous injection of prostaglandin E1 in impotent diabetic men
62. The efficacy and synergy of polypharmacotherapy in primary and salvage therapy of vasculogenic erectile dysfunction
63. Prostaglandin E1: prostaglandin E1 in the study of erectile impotence
64. Distribution and metabolism
65. Die erektile Dysfunktion. Praxis-orientierte Diagnostik der erektilen Dysfunktion (ED) und therapeutische Konsequenzen
66. Comparative usefulness of prostaglandin E1, papaverine and papaverine/phentolamine for the diagnosis of erectile dysfunction in 61 patients
67. Prostaglandin E1 in erectile dysfunction
68. Prostaglandin E1 in male impotence — its diagnostic and therapeutic use in 2000 patients
69. Erektile Dysfunktion. Übersicht und aktueller Stand von Diagnostik und Therapie
70. Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction
71. Intracavernous self-injection therapy with prostaglandin E1 — results of a multicenter study with 189 patients
72. Intracavernous injection of prostaglandin E1 in impotent diabetic men
73. Use of prostaglandin E1 for papaverinefailed erections
74. Metabolic disposition of prostaglandin E1 in man
75. A clinical trial of the intracorporal injection of papaverine/phentolamine vs PGE1 vs topical nitroglycerin ointment in the treatment of erectile dysfunction
76. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence
77. Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction
78. Prostaglandin E1 in erectile dysfunction: efficiency and incidence of priapism
79. Differential diagnosis of organic and functional impotence by the use of 131-iodine labelled human serum albumin
80. Vasoactive intracavernous pharmacotherapy
81. Intracavernosal injection of pharmacological agents in the diagnosis and treatment of impotence
82. Quantitation of pharmacologically-induced penile erections: the value of radionuclide phallography in the objective evaluation of erectile haemodynamics
83. Prostaglandin El in erectile dysfunction: 20 months of experience with 483 patients in a self-injection program
84. Intracavernous prostaglandin E1 (PGE1) in the diagnosis and treatment of erectile dysfunction
85. Intracavernous injection of prostaglandin El in impotent men
86. Intracavernous injection of vasoactive drugs in the rabbit
87. Prostaglandin E1 — 4 years experience of intracavernous injection
88. The use of prostaglandin E1 for diagnosis and treatment of erectile dysfunction
89. Calcitonin-gene-related peptide: a possible role in penile erection and its therapeutic application in impotent patients
90. Comparison of the effect of papaverine hydrochloride and prostaglandin E1 on human corpus cavernosum
91. Prostaglandin concentrations in the semen of fertile men
92. Self-injection with several vasoactive drugs
93. The use of PGEl in arterial rehabilitation in patients affected from cavernous “venous leakage” disease after operations of crural cavernousplastic and binding of the deep dor vein and crural veins
94. Intracavernous injection of papaverine for erectile failure
95. Effects of prostaglandin E1 on penile erection and erectile failure
96. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction
97. Hemodynamic study on erection induced by intracavernous injection of prostaglandin E1
98. Prostaglandins
99. Intracavernosal injection programs
100. Three years' experience with intracavernous self-injection therapy
101. Prostaglandin E1 (PGE1) in diagnosis and treatment of erectile dysfunction
102. Long-term results in self-injection therapy (SIT) with PGE1 in 220 patients
103. Intraindividual comparison of papaverine-phentolamine combination versus prostaglandin E1 in intraca vernous injection therapy for erectile dysfunction
104. Diagnostic evaluation of impotence
105. Intracavernosal injection of prostaglandin E1 as an alternative for papaverine in penile angiography
106. Intracavernous injection of vasoactive drugs for treating erectile impotence (abstract). Hinyokika Kiyo
107. Diagnosis of venous leakage by 133Xe corporeal clearance after intracavernous injection of prostaglandin E1 in poorly responding patients